Published in final edited form as:

J Org Chem. 2015 October 16; 80(20): 10108–10118. doi:10.1021/acs.joc.5b01719.

Design, synthesis and properties of phosphoramidate 2',5'-linked branched RNA: Towards the rational design of inhibitors of the RNA Lariat Debranching Enzyme

Nobuhiro Tago^{†,‡}, Adam Katolik[†], Nathaniel E. Clark[§], Eric J. Montemayor^{§,⊥}, Kohji Seio[‡], Mitsuo Sekine[‡], P. John Hart^{§,||}, and Masad J. Damha^{*,†}

[†]Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montréal, Québec H3A 0B8, Canada

[‡]Department of Life Science, Tokyo Institute of Technology, 4259 Nagatsuta, Midoriku, Yokohama, Kanagawa, 226-8501, Japan

[§]Department of Veterans Affairs, South Texas Veterans Health Care System, San Antonio, TX 78229, United States

^{||}Department of Biochemistry, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States

[⊥]Departments of Biochemistry and Biomolecular Chemistry, University of Wisconsin-Madison, 433 Babcock Dr., Madison, WI 53706, United States

Abstract

Two RNA fragments linked by means of a 2',5' phosphodiester bridge (2' hydroxyl of one fragment connected to the 5' hydroxyl of the other) constitute a class of nucleic acids known as 2'-5' branched RNAs (bRNAs). In this report we show that bRNA analogues containing 2'-5' phosphoramidate linkages (bN-RNAs) inhibit the Lariat Debranching Enzyme, a 2',5'-phosphodiesterase that has recently been implicated in neurodegenerative diseases associated with aging. bN-RNAs were efficiently generated using automated solid phase synthesis and suitably protected branchpoint building blocks. Two orthogonally removable groups, namely the 4-monomethoxytrityl (MMTr) group and the fluorenylmethyl-oxycarbonyl (Fmoc) groups, were evaluated as protecting groups of the 2' amino functionality. The 2'-N-Fmoc methodology was found to successfully produce bN-RNAs on solid-phase oligonucleotide synthesis. The synthesized bN-RNAs resisted hydrolysis by the Lariat Debranching Enzyme (Dbr1), and in addition were shown to attenuate the Dbr1-mediated hydrolysis of native bRNA.

Graphical abstract

Corresponding author: masad.damha@mcgill.ca.

Supporting Information

Additional data such as HPLC analysis, PAGE gels and ¹H, ¹³C, ³¹P NMR spectra are provided. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Introduction

Branched RNAs are important nucleic acid structures generated during messenger RNA (mRNA) maturation in eukaryotic cells. The processing of nascent precursor-mRNA (pre-mRNA) into mature mRNA transcripts involves an editing step known as splicing, during which the non-coding intron sequences are excised and the exon sequences are ligated by the spliceosome in order to generate mature mRNAs.^{1–5} The excised introns adopt a “lariat” configuration that contains an atypical 2',5'-phosphodiester linkage at the branchpoint junction.⁶ The hydrolysis of this linkage is mediated by the lariat debranching enzyme (Dbr1) and is necessary for the degradation of lariat introns after they have been excised by the spliceosome.⁷ Dbr1 also hydrolyzes the 2',5'-phosphodiester linkage found in Y-shaped branched RNA (bRNA), and multi-copy single stranded DNA (msDNA)⁸ and, in addition, Dbr1 activity is involved in the maturation of small nucleolar RNAs (snoRNA) and micro RNAs (miRNA), whose sequences are encoded within introns.^{9–12}

Dbr1 enzymes possess two-domains,¹³ an N-terminal domain that belongs to the metallophosphoesterase (MPEs) superfamily of enzymes,¹⁴ and a C-terminal domain that stabilizes the interaction between lariat RNA and a lengthy internal loop unique to Dbr1 MPEs involved in branchpoint recognition.¹³ Loss of Dbr1 activity results in accumulation of RNA lariats, which are believed to sequester pathogenic forms of TAR DNA binding protein 43 (TDP-43),¹⁵ an RNA-binding protein implicated in neurodegenerative diseases associated with aging.¹⁶ In spinal cord neurons affected by amyotrophic lateral sclerosis (ALS), inclusions enriched in TDP-43 are hallmarks of the disease. The knockdown of Dbr1 activity in yeast, primary rat neurons, and in a selected human neuronal cell line has been shown to offer protection against TDP-43-mediated toxicity.¹⁷ These observations suggest that the identification of inhibitors of Dbr1 activity could open a novel therapeutic avenue for the treatment of ALS and the related disorder, frontotemporal lobar degeneration (FTLD).

Structure-guided synthesis of chemically-modified RNAs represents a useful strategy for identifying potential Dbr1 inhibitors; and the family of non-hydrolyzable bRNAs that mimic the lariat RNA branchpoints seems most promising. Recently, the crystal structure of purified, recombinant Dbr1 from the amoeba *E. histolytica* (Eh) was determined, providing the first picture of an RNA lariat debranching enzyme in the absence of nucleic acids as well as in complex with several synthetic RNAs.¹³ The enzyme engages the branchpoint

adenosine nucleotide in a C2'-endo sugar conformation that, together with stacking of the adenine base between His16 and Tyr64, places the pseudo-equatorial 2' phosphate adjacent to the metal binding center and the 2'-O within hydrogen bonding distance of His91 (Figure 1). The binding interactions between the RNA branchpoint and Dbr1 suggest that the hydrolysis of the 2',5'-phosphodiester linkage proceeds through a S_N2 inversion mechanism in which the bound metal acts as a Lewis acid, increasing the electrophilic character of the 2'-phosphorus and concomitantly increasing the nucleophilicity of the metal-bound water (Figure 1). The cysteine residue (Cys14) in the active site, invariant in Dbr1 enzymes, might facilitate the attack of the metal-bound water by acting as a catalytic base, or by participating in the binding of a second metal ion as is observed in other MPE family members.¹⁴ A putative trigonal bipyramidal transition state intermediate is resolved by proton transfer to the O2' leaving group by the putative catalytic acid His91 (Figure 1).

We previously showed that synthetic bRNAs containing a 2',5'-phosphorothioate (PS) linkage can bind to *Eh*-Dbr1 (C14S mutant), with a 3',5'-phosphodiester linkage in the active site instead of the expected 2',5'-linkage.¹³ The crystal structure of the 2',5'-PS-bRNA •*Eh*Dbr1 complex suggests that the sulfur atom of the phosphorothioate, which has a larger van der Waals radius than that of oxygen ($r_w \sim 0.3 \text{ \AA}$), sterically hinders the accommodation of the phosphorus linkage within the active site. This prompted us to move toward bRNA analogues containing a phosphoramidate (2'N-PO₂-O5') bridge instead, as the size of the nitrogen atom more closely resembles that of the natural oxygen atom in the phosphodiester bond. Furthermore, the 2',5'-phosphoramidate moiety is expected to be more resistant to hydrolysis given that, under neutral or basic conditions, RNH(–) is a poorer leaving group relative to RO(–). Finally, replacing the O2' by N2' is expected to steer the sugar pucker towards the C2'-endo pucker,¹⁸ which corresponds to the sugar conformation found in the bRNA.EhDbr1 co-crystal.

Here, we describe the first solid-phase synthesis of bRNAs containing 2',5'-phosphoramidate moieties ("bN-RNAs"). The synthesized bN-RNAs were evaluated for their biological and chemical stability as well as for their ability to inhibit the activity of Dbr1.

Results & Discussion

Synthesis of branched nucleotides

Our method for unmodified Y-shaped RNA synthesis revolves around the incorporation of a branch-site monomer that allows for the selective growth of each of the three branches regioselectively from any of the hydroxyl positions (5', 3', or 2'). This approach generates a TBDMS-protected bRNA that can be deprotected and released from the support under standard conditions.^{19–20} In this study, we employed the same strategy to build a *phosphoramidate* branchpoint, which requires a protecting group at the 2'-amino position that can be removed selectively (orthogonally) during solid phase synthesis. We considered both the 4-monomethoxytrityl (MMTr)²¹ and fluorenylmethyloxycarbonyl (Fmoc)^{22–23} groups. They can be removed by an acid and base treatment, respectively, under conditions which do not affect the TBDMS or amide-based *N*-protecting groups commonly used in RNA synthesis.

The MMTr and Fmoc-protected phosphoramidites were prepared following two synthetic routes that are described in Scheme 1. Both routes used *N*⁶-Bz-3'-5'-*O,O*-tetraisopropylidisiloxane-2'-deoxy-2'-*N*-amino adenosine (**1**)²⁴ as a starting material. The synthesis of the 2'-*N*-MMTr monomer **5** then started with the protection of the amino group by reacting **1** with MMTr-chloride (MMTr-Cl), affording **2** in excellent yield and was followed by the removal of the 3',5'-*O,O*-disiloxane bridge using tetra-*n*-butylammonium fluoride (TBAF), yielding **3** in 81%. Next, the 5' hydroxyl group was esterified with the orthogonally cleavable levulinyl group. Regioselectivity for the 5' hydroxyl over the 3' hydroxyl was achieved with a levulinic acid substrate that was pre-activated with *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (TBTU) as a coupling reagent. This afforded **4** in 31% yield. Finally, **4** was phosphitylated at the remaining 3' hydroxyl position under standard conditions, thus generating the first branchpoint synthon **5** in 80% yield. To prepare the alternative, 2'-*N*-Fmoc-protected branching unit **9**, (Scheme 1,B) compound **1** was reacted with Fmoc-chloride (FmocCl) in pyridine yielding **6** (89%). Next, the 2',5'-*O,O*-disiloxane bridge was removed using TEA·3HF yielding **7** (75%), followed by the installation of the DMTr group on the 5' hydroxyl (**8**, 94%). Phosphitylation of the remaining 3' hydroxyl of **8** underwent standard condition, thus yielding the final amidite **9** (80%). Before engaging on solid phase bN-RNA synthesis, the reactivity of the branching amidites under coupling conditions was monitored by ³¹P NMR spectra to assess the applicability of the amidite for solid phase bN-RNA synthesis.

Specifically, synthons **5** and **9** were activated with 5-(ethylthio)-1*H* tetrazole (ETT) or 4,5-dicyanoimidazole (DCI) (general RNA/DNA coupling reagents) in CD₃CN and ³¹P NMR spectra were recorded for both compounds (Figure 2, A and Figure 3, A; for amidites **5** and **9** respectively). Immediately after ETT activation (Figure 2, A-ii), the signals corresponding to **5** at 148 and 152 ppm disappeared and were replaced by a signal at 174 ppm. The same signal was also found in the DCI treated sample together with a signal from the starting material at 152 ppm (Figure 2, A-iii). We surmise that the signal of 174 ppm corresponds to a product of cyclization of **5** (Figure 2, B, **5-A**) that is prompted by a nucleophilic attack of the 2'-amino nitrogen onto the activated, electrophilic 3' phosphorus center. In this reaction, the activated intermediate was immediately attacked by the 2'-amino nitrogen so that the activated signal was not detectable by ³¹P NMR. Surprisingly, this cyclic product (**5-A**) displayed notable stability in the presence of excess ethanol even after 24 hours (Figure S1). The ETT activated cyclization was found to be significantly faster than with DCI activation.

In the presence of activating agents, ETT and DCI, the 2'-*N*-Fmoc amidite **9** was rapidly transformed into a mixture of products, as indicated by the new ³¹P-NMR signals detected at 129 ppm and 8 ppm (Figure 3, A-ii, A-iii). However, the signal at 8 ppm, which is expected as hydrolyzed product was the major product in all cases. We hypothesize that the signal at 129 ppm corresponds to 2',3' cyclic structure **9-A** (Figure 3B), or alternatively, a 2',3' cyclic structure resulting from nucleophilic attack by the oxygen carbonyl (Fmoc moiety) rather than the 2'-nitrogen.²⁵ Additionally, the cyclic product exhibited stability against nucleophilic attack after treatment with excess ethanol for greater than 24 hours (Figure S2). The formation of cyclized products in the presence of ETT and DCI potentially precludes the use of amidites **5** and **9** in coupling reactions, particularly in the case of **5** since the 2',3'-

cyclic product may be incapable of reacting with the 5' hydroxyl of a growing oligonucleotide chain, or may create an isomerized product. Consequently, we repeated those experiments in the presence of pre-added ethanol to simulate a coupling reaction. Under these conditions, the 2'-*N*-Fmoc (**9**) compound resisted cyclization to **9-A** relative to the 2'-*N*-MMTr compound (**5**), presumably the result of reduced nucleophilicity due to dispersion of the nitrogen lone pair into the carbamate moiety. The 2'-*N*-MMTr compound can attack the phosphorus of the activated vicinal phosphoramidite species regardless of its steric effect and thereby compete with the alcohol intended for that role while the 2'-*N*-Fmoc is exclusively the target of an alcohol and thereby converted to the desired phosphite triester compound (Figure S3). Consequently, due to its chemical instability under standard coupling conditions, we dismissed the MMTr-protected amidite **5** and engaged in solid phase bRNA synthesis with Fmoc-protected branching amidite **9** only.

Branch RNA synthesis on solid-support

Four 2' phosphoramidate-linked branched RNA molecules (bN-RNAs) were synthesized, each consisting of a dinucleotide or pentanucleotide joined at a branchpoint adenosine unit (Table 1). Sequences of bN-RNAs **2–4** are variations on the sequence of the native yeast *rp51* intron branchpoint. Syntheses of these were performed on an automated DNA synthesizer using a controlled-pore glass solid support and ETT as an activator. In a first step, standard 2'-*O*-TBDMS, 5'-*O*-DMTr, 3'-*O*-phosphoramidite building blocks (**S: standard 3'-*O*-phosphoramidite monomer**) were coupled in order to grow the first 3',5' branch of the desired sequence (Scheme 2). The branchpoint monomer (**9**) was then incorporated through standard coupling conditions and the cycle was resumed to extend the 5'-branch segment using commercially available monomers. With ETT as acid activator, coupling of (**9**) proceeds in 60–80% efficiency as assessed by the trityl assay method. Next, the 5' terminus of the branch was detritylated and capped (Ac₂O) to prevent further extension of this segment. Prior to deblocking the 2'-*N*-Fmoc at the branchpoint, all cyanoethyl groups were removed from the internucleotidic phosphotriesters with a TEA/MeCN treatment (room temperature, 90 minutes). The resulting phosphodiester are then stable against nucleophilic attack by the deprotected 2' amino nitrogen on the vicinal 3' phosphates, a reaction that would lead to subsequent 3'-to-2'-phosphate migration or chain cleavage. Next, the 2'-*N*-Fmoc group was efficiently cleaved with 4-methylpiperidine in DMF (room temperature, 15 minutes). Finally, the remaining 2'-branch segment was generated in the reverse 5'-3' direction using commercially available 2'-*O*-TBDMS, 3'-*O*-DMTr, 5'-*O*-RNA phosphoramidite monomers (**R: reverse 5'-*O*-phosphoramidite monomer**). To minimize steric effects at the 2' branching position, a doubled coupling time and concentration (30 minutes and 0.3 M respectively) was necessary to accelerate the coupling reaction of the first reverse monomer. Deprotection was then performed stepwise, first with 33% ammonia – ethanol (4:1, v/v) treatment (room temperature, 48 hours) followed by desilylation with TEA·3HF (room temperature, 48 hours). Due to the reported acid-labile nature of phosphoramidite linkages,²⁶ alternative desilylation reagents have been considered such as tetra-*n*-butylammonium fluoride (TBAF) in THF and TEA·3HF in 1-methyl-2-pyrrolidinone (NMP) and triethylamine (TEA). The desilylation with non-acidic desilylating reagents afforded better bRNA yields (Table 1). Purification then proceeded first through anion-exchange high performance liquid chromatography (HPLC), and

subsequently through 24% poly-acrylamide gel electrophoresis. Employing this strategy, three bN-RNA sequences were generated in modest yields (Table 1) and tested in chemical and biological assays.

Chemical Stability of the 2',5' Phosphoramidate Linkage

In order to investigate the stability of the novel 2',5' phosphoramidate linkages, synthetic bRNA sequences were exposed to various acidic, basic and fluoride conditions. To clearly assess the stability of the modified branchpoint linkage during solid-phase synthesis, we selected bN-RNA1 as a model sequence considering the chemical inertness of its DNA branches. The results were evaluated by ion-exchange HPLC (Figure S4) and reveal a strong resistance to various basic treatments, particularly those that are commonly used during oligonucleotide cleavage from the solid support, cyanoethyl removal and base deprotection. Conversely, exposing bN-RNA1 to acidic conditions (40% acetic acid, room temperature, 24 hours) resulted in nearly 50% hydrolysis. Indeed, the exposure of bN-RNA1 to TEA·3HF (65 °C, 3 hours) resulted in the complete and selective hydrolysis of the branchpoint phosphoramidate linkage. However, in neutralized fluoride-containing de-silylation conditions, bN-RNA1 did not degrade (Figure 4). These results further highlight the need for optimizing desilylation conditions to improve bRNA synthesis yields (Table 1, conditions b vs. c/d).

Susceptibility of bN-RNA to Debranching Enzyme

In order to assess the compatibility of the 2' phosphoramidate bRNAs as a substrate for Dbr1 2',5' debranching, the modified bN-RNA4, and the equivalent 2'-phosphodiester bRNA5 were ³²P-radiolabeled at their 5' terminus. The debranching reaction was monitored in the presence of 0.5 μM of Dbr1 and the products separated by polyacrylamide gel electrophoresis and visualized by auto-radiography. (Figure 5). These results revealed that the unmodified bRNA5 underwent debranching within seconds, while some of bN-RNA4 still remained after 60 minutes.

Inhibition assays

Synthetic bN-RNAs were evaluated for their ability to attenuate Dbr1 enzymatic activity. The reaction rate was monitored using a ³²P-labelled natural bRNA substrate (bRNA5). The debranching reactions were carried out in the presence of either phosphoramidate modified bN-RNA2 or bN-RNA4). RNA6, a linear control lacking the 2' branch segment, was used as a negative control. To perform those inhibition assays, bN-RNA2, bN-RNA4, and RNA6 were added to solutions containing Dbr1 (20 nM) at increasing concentrations in order to assess their effect on Dbr1 activity. For RNA6 and bN-RNA2, the concentrations were varied from 0 to 10 μM. On the other hand, for bN-RNA4, the concentrations were varied from 0 to 0.5 μM as the attenuation of Dbr1 activity was greater than that of RNA6 and bN-RNA2. The debranched products were separated by polyacrylamide gel electrophoresis and visualized by autoradiography (Figures 6, S5, S6, and S7).

Analysis of the densitometry data clearly indicated that increasing amounts of bN-RNA2 or bN-RNA4 slowed down the activity of Dbr1 (Figure 6B), while the single strand negative control (RNA6) showed no significant effect at any of the tested concentrations (Figure S7).

The IC₅₀ value of bN-RNA4 is estimated to be ~40 nM from analysis of the dose-response curve. The data also suggested that the larger 16mer bN-RNA4 is more potent than the heptamer (bN-RNA2) sequence (Figures S5 and S6). This is fully consistent with crystal structures of bRNA:Dbr1 in which 5 nucleotides of the 2'-arm of the bRNA are observed contacting Dbr1 (Clark, Katolik, *et al.*, to be published). Hence, those bRNAs possessing only 2 nucleotides in the 2'-arm (e.g. bN-RNA2) might have a faster off-rate (or slower on-rate) than those with 5 nucleotides in that arm (e.g. bN-RNA4). Overall, our results suggest that the 16mer (bN-RNA4) sequence binds more strongly to Dbr1 than the shorter sequence (bN-RNA2).

Given that bN-RNA2 and bN-RNA4 are processed slowly by their target enzyme, they might be better described as pseudo-substrate inhibitors or alternate substrate inhibitors.²⁷ *A priori*, the on- and off-rates for the nearly identical wild type and P-amidate bRNAs (e.g., bRNA6 vs bN-RNA4) should be the same, as substituting a 2'-O with a 2'-N on the scissile phosphate is not expected to significantly alter those parameters; in fact, the only part of Dbr1 interacting with the 2'-N is His91¹³ (Figure 1). Hence, we postulate that the inhibition observed in the presence of the bN-RNAs probably comes from the "slow" hydrolysis step in the P-amidate linkage compared to the wild type phosphodiester bond.

Conclusions

This study is the first to report the synthesis of a bRNA containing a 2',5' phosphoramidate linkage (bN-RNA). We have successfully prepared a branchpoint nucleotide building block for the development of modified bN-RNAs with 2',5' phosphoramidate linkages. We have evaluated both the 2'-N-Fmoc and 2'-N-MMTr groups to protect the 2' amino function during solid phase synthesis of the bN-RNAs. ³¹P NMR spectroscopy indicated that both branch monomers underwent cyclization under coupling conditions, but the 2'-N-Fmoc protected monomer seemed to cyclize to a much lower rate and was consequently deemed suitable for solid-phase synthesis. The resulting synthetic bN-RNAs were additionally tested for their stability under DNA/RNA deprotection conditions. It was found that the 2',5' phosphoramidate linkage at the branchpoint was acid labile and consequently hydrolyzed in the acidic fluoride-containing desilylation mixtures required for 2'-O-TBDMS removal. However, the use of desilylation solutions at neutral pH significantly improved the total recovery yield of bN-RNA synthesis. The Bn-RNAs were tested as substrates for the Debranching Enzyme (Dbr1). While the 2'-5' phosphoramidates were substrates for Dbr1, they are significantly more resistant to the action of the enzyme than the natural bRNAs of identical sequence. Finally, the 2' phosphoramidate-linked bRNAs were evaluated for their ability to inhibit Dbr1, an effect that may be applicable in work seeking to reduce the toxicity of TDP-43 involved in amyotrophic lateral sclerosis (ALS). Since complete inhibition of debranching activity is lethal²⁸, care must be taken to design inhibitors with very specific pharmacological properties. The structures presented in this work may help guide such efforts since, theoretically, there could be a benefit in using an alternate substrate inhibitor over a full inhibitor as a therapeutic agent. That is, a slowly hydrolyzed alternate substrate inhibitor would permit a spike of intron lariats to accumulate (and sequester existing TDP-43 pool), and upon hydrolysis of the alternate inhibitor, "normal" Dbr1

activity would be restored. We believe our results will help guide the rational design of inhibitors that may represent novel therapeutic agents to treat neurodegenerative disease.

Experimental Section

General information

All chemicals were purchased from commercial sources and were used as received. Where required, solvents were dried on molecular sieves (4 Å) overnight.

Solid Phase Synthesis of Branched RNAs

Materials and reagents—Branched RNAs were synthesized using DNA/RNA synthesizer (ABI) on a 1 μmol scale of unilink support CPG resin (ChemGenes, 22 μmol/g). Conventional and reverse 2' TBDMS and bis-cyanoethyl-*N,N*-diisopropyl phosphoramidite were used (0.15 M in MeCN). Dissolved phosphoramidites were activated with required activator (5-ethylthio-1*H*-tetrazole (ETT) or 4,5-dicyano imidazole (DCI) (0.25 M in MeCN)). ETT was used for the synthesis all bN-RNAs shown in Table 1. Capping was carried out following every coupling reaction by the simultaneous delivery of acetic anhydride in pyridine/THF and *N*-methylimidazole (16% in THF) and contacting the solid support for 6 seconds. Oxidation of phosphite triester intermediates was carried with 0.1 M iodine in pyridine/H₂O/THF (20 seconds). A solution of 3% trichloroacetic acid in THF, delivered over 1.8 minutes, was used to deblock DMTr groups. After elongation towards 3' to 5', cyanoethyl (CNEt) phosphate was de-protected using anhydrous triethylamine/MeCN (2:3, v/v) over 1.3 hours. Fmoc protection on 2'-amino of branch site was cleaved using 10% 4-methylpiperidine in anhydrous DMF over 15 minutes. Oligonucleotides were de-protected and cleaved from the solid support using NH₄OH:EtOH (3:1, v/v) or concentrated ammonium hydroxide solution. Then TBDMS groups were cleaved with TEA·3HF-NMP-TEA (3:2:3, v/v/v) at 65 °C for 3 hours or 1 M TBAF in THF at ambient temperature for 8 hours.

Purification of bRNAs

Synthesized compounds were purified by HPLC using an anion exchange column (Protein PAK DEAE 5PW 21.5 mm × 15 cm). The buffer system consisted of water as solution A and 1 M aqueous lithium perchlorate as solution B at a flow rate of 4 mL/min. The gradient was 0–40% of buffer B over 50 min at 60 °C. The desired peak was collected and then desalted using a pre-eluted size exclusion column filled with NAP-25 matrix. The column was eluted with sterile water and 7 × 1 mL fractions were collected. Each fraction was quantified by absorbance (λ = 260 nm). Analytical polyacrylamide gel electrophoresis was used to assess the quality of purified products, and additional preparative polyacrylamide purification of bRNAs was performed as needed. The mass of each purified compound was confirmed by ESI-TOF.

Analytical HPLC

The crude or purified samples were analyzed by anion exchange column (Protein DEAE 5PW 7.5 × 75 mm). The buffer system was the same as purification. The gradient was 0–24% of buffer B over 30 minutes at 65 °C.

Radio-Labeling of the bRNA samples

(Warning: cautions must be taken with ^{32}P , including shielding, decontamination, and respecting CNSC or other local radiation safety regulations) In a 20 μL total volume, bRNA (100 pmol, 5 μM) was incubated with $\gamma\text{-}^{32}\text{P}\text{-ATP}$ (50–150 μCi), 2000 units T4 polynucleotide kinase in 70 mM Tris-HCl pH 7.6, 10 mM MgCl_2 , 5 mM DTT. After incubation at 37 $^\circ\text{C}$ for 1 hour, a NAP-10 column equilibrated in water was used to remove unincorporated $\gamma\text{-}^{32}\text{P}\text{-ATP}$ from labeled bRNA. The resulting samples were dried down and activity quantitated. The size exclusion column provided a rough separation of labeled oligonucleotide (which eluted in 2nd, 3rd and 4th fractions) from the free $\gamma\text{-}^{32}\text{P}\text{-ATP}$ (which eluted in subsequent fractions).

^{32}P Autoradiography assays

(Warning: cautions must be taken with ^{32}P , including shielding, decontamination, and respecting CNSC or other local radiation safety regulations) 12% (19:1) polyacrylamide gels in 7 M urea and 1 $\times$ TBE (89 mM tris base, 89 mM boric acid, 2 mM EDTA) were used in both debranching and inhibition assays. For each lane in the gel, approximately 100–1000 microcuries of labeled RNA were loaded. The running buffer contained 0.5 $\times$ TBE buffer (44.5 mM tris base, 44.5 mM boric acid, 1 mM EDTA) and samples were electrophoresed at 1000 V for 3 h. X-ray film was placed on each gel and exposed overnight and developed using commercial developer and fixer solutions.

Debranching Assays

Reactions were carried out in a 20 μL total volume and a 10:1 substrate enzyme ratio. The reactions contained: the substrate (bN-RNA4 or bRNA5 (5 μM) + respective $^{32}\text{P}\text{-bN-RNA4}$ or $^{32}\text{P}\text{-bRNA5}$ (low nM, 1,000–20,000 cpm)), Dbr1 (0.5 μM), NaCl (100 mM), HEPES (10 mM, pH 7.0–7.6), tris(2-carboxyethyl)phosphine (0.5 mM) and Tween20 (0.005% v/v). Specifically, a 9 μL mixture containing the substrate was added to 10 μL of the 2 $\times$ salt buffer and the reactions were initiated by adding 1 μL of Dbr1 (10 μM). Un-labeled substrate was mixed with the 5'- ^{32}P substrate because the exact concentration of radiolabeled substrates was not precisely established. Therefore, a known and much greater concentration of matching unlabeled bRNA was added to each labeled bRNA, and the concentration of unlabeled bRNA used as a surrogate for the total substrate concentration. The reaction was analyzed at two time points (30 sec and 1 h). Each time 10 μL of the reaction mixture was withdrawn and added to 14 μL of deionized formamide gel loading buffer to stop the reaction, and immediately frozen in solid CO_2 . Next, the samples were heated to 95 $^\circ\text{C}$ for 5 min and loaded onto a 12% polyacrylamide gel and developed as described above. Synthetic $^{32}\text{P}\text{-RNA6}$ was run as a control to verify that the correct debranched product was being formed.

Dbr1 inhibition assays

Reactions were carried out in a 10 μL total volume and a 62.5:1 substrate:enzyme ratio. The reaction mixture contained: Dbr1 (20 nM), NaCl (100 mM), HEPES (10 mM, pH 7.0–7.6), tris(2-carboxyethyl)phosphine (0.5 mM), Tween20 (0.005% v/v), BSA (0.05 mg/ml), substrate (bRNA5 (1.25 μM) + $^{32}\text{P}\text{-bRNA5}$ (estimated <0.2 μM , 100–1000 cpm)) and the

bN-RNA inhibitor (conc. specified in Figure 6). More specifically, the reactions were initiated by combining 5 μ L of a freshly thawed (-80°C to r.t.) aliquot containing Dbr1 (40 nM), NaCl (200 mM), HEPES (20 mM pH 7.0–7.6), tris(2-carboxyethyl)phosphine (1 mM), Tween20 (0.01% v/v), and BSA (0.1 mg/ml) with 5 μ L of a mixture containing the inhibitor (twice the final reaction concentration), and the substrate (bRNA5 (2.5 μ M) + ^{32}P -bRNA5 (estimated $<0.4\ \mu\text{M}$). Following initiation, the reactions were constantly mixed for the first 30 or 60 seconds by pipetting. Following an additional period (30 seconds or 1 min), 5 μ L aliquots of the reaction mixtures were removed and added to 7 μ L of deionized formamide gel loading solution to stop the reaction, and immediately frozen. Next, the samples were together heated to 95°C for 5 min and loaded onto a 12% polyacrylamide gel and developed as above. On the same gel, a parallel lane was supplemented with synthetic ^{32}P -RNA6 to serve as a control for the expected product of debranching. The developed X-ray films were scanned and densitometrically analyzed by the program ImageJ64. Next, the % cleavage value was obtained from each lane by dividing the density (quantity of radiation) of hydrolyzed product by the sum of the density of the substrate and product. This ratio was then normalized so that 100% represented the uninhibited reaction, and this allowed the averaging of two assays. Finally, the values were plotted into Graphpad Prism, which fitted a curve and obtained the IC_{50} for bN-RNA4.

^{31}P NMR study of compounds 5 and 9

40 mg of each nucleoside was dissolved in 400 μ L of dried deuterated acetonitrile. A required activator such as 4,5-dicyano imidazole (DCI) or 5-ethylthio-1*H*-tetrazole (ETT) was added to make the solution 0.25 M, which is the normal procedure in a DNA/RNA coupling method. Those procedures were done in a NMR tube.

N^6 -Benzoyl-2'-deoxy-2'-amino-3',5'-O-[1,1,3,3-tetrakis(1-methylethyl)-1,2-disiloxanediyl]-adenosine (1)—The compound was synthesized according to previously published protocols²⁴.

N^6 -Benzoyl-2'-deoxy-2'-[(4-methoxytrityl)amino]-3',5'-O-[1,1,3,3-tetrakis(1-methylethyl)-1,2-disiloxanediyl]-adenosine (2)—Compound **1** (1.70 mg, 2.78 mmol) was co-evaporated with dried pyridine for 3 times, then dissolved in dried pyridine (27.8 mL) and the reaction was stirred at ambient temperature under argon. Next, 4-methoxytrityl chloride (1.028 g, 3.33 mmol) was added into the flask. After 8 hours, CH_2Cl_2 and NaHCO_3 (sat. aq.) were added. The organic phase was washed three times with NaHCO_3 and once with brine. The combined aqueous layers were extracted with CH_2Cl_2 once. The combined organic layers were dried over Na_2SO_4 , filtered and concentrated. The residue was purified by flash column chromatography (SiO_2 , 3:7 hexane/ethyl acetate) to yield compound **3** (2.348 g, 95%) as an amorphous yellow solid: ^1H NMR (400 MHz, acetonitrile- d_3) δ 9.21 (s, 1H), 8.46 (s, 1H), 7.99 (d, $J = 7.6$ Hz, 2H), 7.70 – 7.59 (m, 2H), 7.60 – 7.51 (m, 2H), 7.46 – 7.35 (m, 4H), 7.26 – 7.07 (m, 8H), 6.65 (dt, 2H), 5.34 (d, $J = 3.5$ Hz, 1H), 4.71 (t, $J = 6.6$ Hz, 1H), 4.31 (dt, $J = 6.8, 3.5$ Hz, 1H), 4.21 (td, $J = 6.3, 3.2$ Hz, 1H), 3.94 (dd, $J = 12.4, 3.3$ Hz, 1H), 3.79 (dd, $J = 12.4, 6.1$ Hz, 1H), 3.72 (d, $J = 3.5$ Hz, 1H), 3.69 (s, 3H), 1.22 – 0.90 (m, 28H); ^{13}C NMR (101 MHz, acetonitrile- d_3) δ 159.2, 152.5, 147.8, 147.4, 144.6, 138.5, 133.5, 131.1, 129.7, 129.4, 129.2, 129.0, 128.9, 128.8, 127.6, 127.5, 125.8, 118.3, 114.0,

90.2, 84.5, 72.2, 70.9, 63.1, 59.1, 55.8, 17.8, 17.6, 17.6, 17.5, 17.4, 14.3, 13.9, 13.9, 13.7, 1.9, 1.9, 1.8, 1.7, 1.6, 1.7, 1.5, 1.4, 1.4, 1.3, 1.2, 1.2, 1.1, 1.0, 1.0, 0.9, 0.8, 0.7, 0.6; HRMS (ESI Q-TOF) m/z : $[M+Na]^+$ calcd for $C_{49}H_{60}N_6O_6Si_2Na$ 907.4005; found 907.3990.

N⁶-Benzoyl-2'-deoxy-2'-[(4-methoxytrityl)amino]-adenosine (3)—Compound **2** (2.15 mg, 2.4 mmol) was dissolved in THF (6.4 mL) and the reaction was stirred at ambient temperature under argon. 1 M Tetrabutylamine trihydrofluoride (TBAF) in THF (5.6 mL, 5.6 mmol) was then added into the flask. After 1 hour, silicagel (SiO_2 , 7.5 g) was added to quench the excess of TBAF. The mixed solution was concentrated then directly loaded on a flush column chromatography (SiO_2 , 1:1 to 1:9, hexane/ethylacetate) to yield compound **3** (1.25 g, 81%) as a white solid: 1H NMR (500 MHz, chloroform- d) δ 9.14 (s, 1H), 8.61 (s, 1H), 8.25 (s, 1H), 8.08 (d, 2H), 7.65 (t, J = 7.5 Hz, 1H), 7.57 (t, J = 7.6 Hz, 2H), 7.19 (dd, 4H), 7.12 – 6.96 (m, 6H), 6.60 (d, J = 8.9 Hz, 1H), 5.84 (d, J = 12.1, 2.1 Hz, 1H), 5.78 (d, J = 8.9 Hz, 1H), 4.13 (q, J = 9.2, 8.7 Hz, 1H), 4.06 (s, 1H), 3.80 (d, J = 12.9 Hz, 1H), 3.70 (s, 3H), 3.45 (t, J = 12.5 Hz, 1H), 2.90 (t, J = 4.5 Hz, 1H), 2.79 (d, J = 10.7 Hz, 1H), 1.65 (s, 4H), 1.50 (d, J = 4.3 Hz, 1H). ^{13}C NMR (126 MHz, chloroform- d) δ 164.5, 158.3, 152.2, 150.9, 150.3, 146.1, 146.0, 143.4, 137.8, 133.6, 133.1, 129.5, 129.1, 128.1, 128.1, 128.0, 128.0, 128.0, 126.9, 124.9, 113.4, 109.9, 92.0, 88.7, 77.4, 77.2, 76.9, 71.3, 69.8, 63.5, 60.0, 55.3.; HRMS (ESI Q-TOF) m/z : $[M+Na]^+$ calcd for $C_{37}H_{34}N_6O_5Na$ 665.2483; found 665.2481.

N⁶-Benzoyl-2'-deoxy-5'-O-levulinyl-2'-[(4-methoxytrityl)amino]-adenosine (4)—*O*-(Benzotriazol-1-yl)-*N,N,N',N'*-tetramethylammonium tetrafluoroborate (TBTU, 889 mg, 2.77 mmol) was dissolved in DMF (8.28 mL) and *N,N*-diisopropylethylamine (0.92 mL) and stirred at room temperature under argon. Freshly distilled levulinic acid (281 μ L, 2.77 mmol) was added, and the reaction was stirred at room temperature for 30 minutes. Compound **3** (594 mg, 0.92 mmol) was dried under a vacuum in a flask with a magnetic stirrer. The solution of TBTU/levulinic acid reaction was added dropwise for 10 min to the nucleoside and stirred at room temperature for 8 hours. Next, CH_2Cl_2 and $NaHCO_3$ (sat. aq.) were added, and the mixture was separated. The organic phase was washed three times with $NaHCO_3$. The combined aqueous layers were extracted once with CH_2Cl_2 . Next, the combined organic extracts were washed once with brine and subsequently combined with the original organic layer, dried with Na_2SO_4 , filtered and concentrated. The residue was purified by column chromatography (SiO_2 , 1:1 $\rightarrow$ 1:9 Hexane/Ethyl acetate) to yield compound **4** (194 mg, 31%) as an amorphous white solid.: 1H NMR (400 MHz, DMSO- d_6) δ 11.27 (s, 1H), 8.70 (s, 1H), 8.58 (s, 1H), 8.14 – 8.06 (m, 2H), 7.66 (d, J = 7.3 Hz, 1H), 7.58 (t, J = 7.6 Hz, 2H), 7.29 – 7.02 (m, 12H), 6.65 (d, J = 8.8 Hz, 2H), 6.10 (d, J = 8.6 Hz, 1H), 5.51 (d, J = 3.9 Hz, 1H), 4.15 – 3.87 (m, 4H), 3.66 (s, 3H), 3.11 (d, J = 10.0 Hz, 1H), 2.68 (t, J = 6.5 Hz, 2H), 2.43 – 2.34 (m, 2H), 2.16 (t, J = 4.2 Hz, 1H), 2.09 (s, 3H); ^{13}C NMR (101 MHz, chloroform- d) δ 206.6, 172.4, 158.4, 152.7, 152.2, 145.9, 142.4, 137.5, 133.0, 130.0, 129.5, 129.1, 128.2, 128.1, 128.0, 126.9, 113.4, 113.4, 92.1, 88.8, 83.7, 77.5, 77.4, 77.3, 77.2, 76.8, 71.3, 70.5, 70.1, 64.3, 60.5, 58.1, 55.4, 53.6, 38.0, 31.1, 30.0, 27.9, 8.2, 1.3, 1.2.; HRMS (ESI Q-TOF) m/z : $[M+Na]^+$ calcd for $C_{42}H_{40}N_6O_7Na$ 763.2851; found 763.2841.

N⁶-Benzoyl-2'-deoxy-5'-O-levulinyl-2'-[(4-methoxytrityl)amino]-adenosine 3'- (2-cyanoethyl N,N-diisopropylphosphoramidite) (5)—Compound 4 (490 mg, 0.66 mmol) was dissolved in 6.6 mL CH₂Cl₂, and the mixture was stirred at 0 °C under argon. N,N-diisopropylethylamine (461 μL, 2.64 mmol) was added, followed by 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (295 μL, 1.32 mmol) then stirred at ambient temperature. After 2 hours, CH₂Cl₂ and NaHCO₃ (sat aq) were added, and the mixture was separated. The organic phase was washed three times with NaHCO₃. The combined aqueous layers were extracted once with CH₂Cl₂. Next the combined organic extracts were washed once with brine and subsequently combined with the original organic layer, dried with Na₂SO₄, filtered, and concentrated. The residue was purified by column chromatography (SiO₂, 7:3 to 5:3, Hexane/CH₂Cl₂). The fractions containing compound 4 were concentrated and then dissolved again with diethylether. The organic solvent was washed with NaHCO₃ for four times to yield pure compound 5 (417 mg, 80%) as an amorphous white solid ¹H NMR (500 MHz, chloroform-*d*) δ 9.11 (s, 1H), 8.70 – 8.54 (m, 1H), 8.17 – 8.12 (m, 1H), 8.06 (d, *J* = 7.7 Hz, 2H), 7.61 (t, *J* = 7.4 Hz, 1H), 7.53 (t, *J* = 7.6 Hz, 2H), 7.31 – 7.22 (m, 4H), 7.18 – 7.12 (m, 2H), 7.12 – 7.02 (m, 5H), 6.64 – 6.49 (m, 2H), 6.13 – 5.93 (m, 1H), 4.53 – 4.36 (m, 1H), 4.32 (t, *J* = 5.9 Hz, 1H), 4.21 – 4.09 (m, 2H), 3.70 (d, *J* = 3.0 Hz, 3H), 3.67 – 3.54 (m, 3H), 3.06 (d, *J* = 9.3 Hz, 1H), 2.99 – 2.90 (m, 1H), 2.77 – 2.65 (m, 2H), 2.60 – 2.23 (m, 4H), 2.20 – 2.14 (m, 3H), 1.98 (s, 1H), 1.16 (t, 12H).; ¹³C NMR (126 MHz, chloroform-*d*) δ 206.7, 206.6, 172.5, 172.3, 164.7, 158.2, 152.6, 152.4, 152.2, 152.1, 149.6, 149.6, 146.2, 146.1, 143.5, 143.3, 137.8, 137.7, 134.0, 133.1, 132.9, 129.9, 129.7, 129.6, 129.4, 129.2, 129.0, 128.7, 128.4, 128.2, 128.0, 126.9, 126.6, 124.4, 124.3, 117.6, 114.0, 113.5, 113.1, 112.7, 89.8, 89.5, 82.9, 82.7, 82.0, 81.8, 77.5, 77.3, 77.0, 74.9, 74.8, 74.6, 74.5, 70.2, 70.1, 64.1, 59.0, 58.8, 58.6, 58.5, 56.0, 55.5, 55.4, 54.9, 44.1, 44.0, 43.6, 43.5, 43.1, 43.0, 38.0, 30.4, 30.2, 30.0, 29.8, 27.9, 27.8, 27.7, 25.4, 25.3, 25.2, 24.9, 24.8, 24.8, 24.7, 24.6, 20.4, 20.4, 20.2, 20.2, 20.0, 20.0.; 31P NMR (202 MHz, chloroform-*d*) δ 154.0, 151.1.; HRMS (ESI Q-TOF) *m/z*: [M+H]⁺ calcd for C₅₁H₅₈N₈O₈P 941.4110; found 941.4123.

N⁶-Benzoyl-2'-deoxy-2'-[(9-fluorenylmethyloxycarbonyl)amino]-3',5'-O-[1,1,3,3-tetra kis(1-methylethyl)-1,2-disiloxanediyl]-adenosine (6)—Compound 1 (1.2 g, 1.96 mmol) was co-evaporated with dried pyridine for 3 times, then dissolved in dried pyridine (20 mL) and the reaction was stirred at ambient temperature under argon. Next, fluorenylmethyloxycarbonyl chloride (556 mg, 2.15 mmol) was supplemented into the flask. 30 minutes later, the reaction was quenched by the addition of H₂O (5 mL). CH₂Cl₂ and NaHCO₃ (sat. aq.) were subsequently added and the organic phase was washed three times with NaHCO₃. The combined aqueous layers were extracted with CH₂Cl₂ once and the combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was purified by flush column chromatography (SiO₂, 7:3 hexane/ethyl acetate) to yield compound 6 (1.43 g, 87%) as an amorphous yellow solid; ¹H NMR (500 MHz, chloroform-*d*) δ 9.00 (s, 1H), 8.76 (s, 1H), 8.16 (s, 1H), 8.01 (d, *J* = 7.6 Hz, 2H), 7.76 (d, *J* = 7.4 Hz, 2H), 7.60 (d, *J* = 7.4 Hz, 1H), 7.53 (t, *J* = 7.5 Hz, 4H), 7.39 (s, 2H), 7.28 (s, 2H), 6.05 (s, 1H), 5.75 (s, 1H), 5.32 (s, 1H), 4.65 (d, *J* = 7.3 Hz, 1H), 4.41 (dd, *J* = 10.5, 7.0 Hz, 1H), 4.36 (d, *J* = 6.5 Hz, 1H), 4.20 (s, 1H), 4.07 (s, 3H), 1.23 – 0.99 (m, 28H).; ¹³C NMR (126 MHz, chloroform-*d*) δ 164.6, 153.0, 149.9, 143.7, 142.6, 141.5, 134.0, 133.0, 129.1, 128.0, 127.2, 125.2, 123.7, 120.3, 88.8, 84.0, 77.5, 77.4, 77.2, 77.0, 70.5, 67.4, 62.9, 57.2, 47.3,

17.7, 17.6, 17.5, 17.4, 17.2, 13.4, 13.4, 13.1, 12.9.; HRMS (ESI Q-TOF) m/z : $[M+Na]^+$ calcd for $C_{44}H_{54}N_6O_7Si_2Na$ 857.3465; found 857.3485.

***N*⁶-Benzoyl-2'-deoxy-2'-[(9-fluorenylmethyloxycarbonyl)amino]-adenosine (7)**

—Compound **6** (1.43 g, 1.71 mmol) was dissolved in THF (7.2 mL) and the reaction was stirred at ambient temperature under argon. TEA·3HF (0.48 mg, 0.91 mmol) was then added into the flask. The reaction was stirred for 10 hours and subsequently quenched by the addition of excess methoxytrimethylsilyl. After 2 hours, the reaction mixture was concentrated and the residue was purified by flush column chromatography (SiO_2 , 3% to 5% methanol in CH_2Cl_2) to yield compound **7** (0.74 g, 73%) as an amorphous solid; 1H NMR (500 MHz, $DMSO-d_6$) δ 11.24 (s, 1H), 8.76 (s, 1H), 8.68 (s, 1H), 8.06 (d, $J = 7.7$ Hz, 2H), 7.85 (d, $J = 7.6$ Hz, 2H), 7.70 – 7.59 (m, 3H), 7.55 (t, $J = 7.4$ Hz, 3H), 7.38 (t, $J = 7.4$ Hz, 2H), 7.25 (dt, $J = 30.3, 7.5$ Hz, 2H), 6.18 (d, $J = 8.4$ Hz, 1H), 5.78 (d, $J = 4.4$ Hz, 1H), 5.24 (t, $J = 5.6$ Hz, 1H), 5.10 – 4.91 (m, 1H), 4.30 (s, 1H), 4.28 – 4.19 (m, 1H), 4.18 – 4.06 (m, 3H), 3.77 – 3.57 (m, 2H), 3.36 (s, 1H).; ^{13}C NMR (126 MHz, $DMSO-d_6$) δ 165.6, 155.9, 152.4, 151.7, 150.5, 143.7, 143.3, 140.7, 133.4, 132.5, 128.5, 128.5, 127.6, 127.0, 125.9, 125.4, 125.2, 120.1, 87.3, 85.7, 70.2, 65.9, 61.7, 56.8, 48.6, 46.5, 40.0, 39.9, 39.8, 39.7, 39.6, 39.5, 39.4, 39.2, 39.0, 38.9.; HRMS (ESI Q-TOF) m/z : $[M+H]^+$ calcd for $C_{32}H_{29}N_6O_6$ 593.2143; found 593.2128.

***N*⁶-Benzoyl-2'-deoxy-5'-O-[4,4'-dimethoxytrityl]-2'-[(9-fluorenylmethyloxycarbonyl)amino]-adenosine (8)**

—Compound **7** (170 mg, 0.29 mmol) was co-evaporated with dried pyridine for 3 times, then dissolved in dried pyridine (2.9 mL) and the mixture was stirred at ambient temperature under argon. 4,4'-*O,O*-dimethoxytrityl chloride (117 mg, 0.34 mmol) was then added into the reaction mixture, and this was stirred for 4 hours and quenched through the addition of excess methanol (2 mL). Next, CH_2Cl_2 and $NaHCO_3$ (sat. aq.) were added and the organic phase was washed three times with $NaHCO_3$. The combined aqueous layers were extracted with CH_2Cl_2 once. The combined organic layers were dried over Na_2SO_4 , filtered and concentrated. The residue was purified by flush column chromatography (SiO_2 , 8:2, ethylacetate/hexane) to yield compound **8** (185 mg, 72%) as an amorphous solid; 1H NMR (500 MHz, $chloroform-d$) δ 9.20 (s, 1H), 8.71 (s, 1H), 8.37 (s, 1H), 7.94 (d, $J = 7.6$ Hz, 2H), 7.67 – 7.51 (m, 3H), 7.49 – 7.37 (m, 6H), 7.31 (d, $J = 8.5$ Hz, 5H), 7.28 – 7.22 (m, 3H), 7.19 (d, $J = 7.2$ Hz, 1H), 7.14 – 7.07 (m, 2H), 6.78 (d, $J = 8.2$ Hz, 4H), 6.48 (d, $J = 8.0$ Hz, 1H), 6.31 (d, $J = 7.9$ Hz, 1H), 5.10 (d, $J = 6.9$ Hz, 1H), 4.67 (s, 1H), 4.48 (s, 1H), 4.33 (s, 1H), 4.29 – 4.18 (m, 1H), 3.98 (s, 1H), 3.73 (s, 6H), 3.51 – 3.31 (m, 2H), 2.38 (s, 1H).; ^{13}C NMR (126 MHz, $chloroform-d$) δ 165.1, 158.8, 156.6, 152.8, 152.4, 149.5, 144.6, 143.9, 143.8, 142.2, 141.4, 141.3, 135.8, 135.7, 133.7, 133.1, 130.3, 129.1, 128.4, 128.2, 128.1, 127.9, 127.8, 127.2, 127.2, 125.1, 125.1, 123.2, 120.1, 120.1, 113.5, 87.0, 86.5, 85.8, 77.6, 77.5, 77.3, 77.0, 72.0, 67.1, 64.0, 58.1, 55.4, 47.2.; HRMS (ESI Q-TOF) m/z : $[M+Na]^+$ calcd for $C_{53}H_{46}N_6O_8Na$ 917.3269; found 917.3282.

***N*⁶-Benzoyl-2'-deoxy-5'-O-[4,4'-dimethoxytrityl]-2'-[(9-fluorenylmethyloxycarbonyl)amino]-adenosine 3'-(2-cyanoethyl *N,N*-diisopropylphosphoramidite) (9)**

—Compound **8** (520 mg, 0.58 mmol) was co-

evaporated first with dried pyridine, followed by toluene and finally CH₂Cl₂. This was done 3 times with each solvent. Next, the dried compound was dissolved in anhydrous CH₂Cl₂ (5.8 mL) and the reaction was stirred at ambient temperature under argon. *N,N*-diisopropylethylamine (222 μ L, 2.33 mmol) was added, followed by 2-cyanoethyl *N,N*-diisopropylchlorophosphoramidite (259 μ L, 1.16 mmol) and this was stirred at ambient temperature over 1.5 hours. Next, CH₂Cl₂ and NaHCO₃ (sat. aq.) were added and the organic phase was washed three times with NaHCO₃. The combined aqueous layers were extracted with CH₂Cl₂ once. The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash column chromatography (SiO₂, 5:5 to 3:7, ethylacetate/hexane) to yield compound **9** (500 mg, 79%) as an amorphous solid; ¹H NMR (500 MHz, chloroform-*d*) δ 9.12 (s, 1H), 8.77 (d, *J* = 9.3 Hz, 1H), 8.33 (d, *J* = 26.3 Hz, 1H), 8.02 (d, *J* = 7.6 Hz, 2H), 7.74 (t, *J* = 7.2 Hz, 2H), 7.59 (t, *J* = 7.4 Hz, 1H), 7.51 (t, *J* = 7.7 Hz, 4H), 7.47 – 7.40 (m, 2H), 7.41 – 7.17 (m, 11H), 6.81 (d, *J* = 8.6, 2.9 Hz, 4H), 6.26 – 6.02 (m, 1H), 5.87 – 5.48 (m, 1H), 5.31 – 5.03 (m, 1H), 4.77 – 4.54 (m, 1H), 4.53 – 4.20 (m, 3H), 4.18 – 4.05 (m, 1H), 3.91 – 3.56 (m, 7H), 3.57 – 3.42 (m, 1H), 3.36 (dd, *J* = 10.6, 3.6 Hz, 1H), 2.46 (dd, *J* = 5.9 Hz, 1H), 2.32 (t, *J* = 6.4 Hz, 1H), 2.02 – 1.84 (m, 1H), 1.35 – 1.02 (m, 14H).; ¹³C NMR (126 MHz, chloroform-*d*) δ 164.6, 158.7, 156.0, 153.0, 152.9, 152.4, 149.6, 149.6, 144.4, 143.7, 141.8, 141.7, 141.4, 135.5, 133.9, 132.8, 130.2, 130.2, 130.2, 129.0, 128.3, 128.2, 128.1, 127.9, 127.8, 127.2, 125.1, 125.0, 124.9, 124.8, 123.2, 120.1, 117.5, 117.4, 113.4, 87.0, 86.5, 85.1, 77.4, 77.4, 77.2, 77.1, 76.9, 67.3, 66.6, 63.4, 58.7, 58.5, 56.9, 56.6, 55.4, 55.4, 47.3, 47.1, 43.7, 43.6, 43.5, 24.9, 24.7, 24.7, 24.6, 20.4, 20.0.; ³¹P NMR (202 MHz, chloroform-*d*) δ 152.9, 151.7.; HRMS (ESI Q-TOF) *m/z*: [M + Na]⁺ calcd for C₆₂H₆₃N₈O₉PNa 1117.4348; found 1117.4331.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by grants from the National Science and Engineering Research Council (to M.J.D.), Department of Veterans Affairs (1 I01 BX002580, to PJH), the Robert A. Welch Foundation (AQ-1399, to PJH.), the National Science Foundation (DBI-0905865, to E.J.M.) the Judith and Jean Pape Adams Charitable Foundation (to PJH), the Barshop Institute for Longevity and Aging Studies (5 T32 AG021890, to E.J.M. and N.E.C.), and a Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from a Japan Society for the Promotion of Science (JSPS).

References

1. Sharp PA. Cell. 1981; 23:643. [PubMed: 7226224]
2. Ruskin B, Green MR. Science. 1985; 229:135. [PubMed: 2990042]
3. Matera AG, Wang Z. Nat Rev Mol Cell Biol. 2014; 15:108. [PubMed: 24452469]
4. Will CL, Lührmann R. Cold Spring Harb Perspect Biol. 2011; 3:a003707. [PubMed: 21441581]
5. Brody E, Abelson J. Science. 1985; 228:963. [PubMed: 3890181]
6. Murphy WJ, Watkins KP, Agabian N. Cell. 1986; 47:517. [PubMed: 3779835]
7. Chapman KB, Boeke JD. Cell. 1991; 65:483. [PubMed: 1850323]
8. Nam K, Hudson RH, Chapman KB, Ganeshan K, Damha MJ, Boeke JD. J Biol Chem. 1994; 269:20613. [PubMed: 7519612]
9. Ooi SL, Samarsky DA, Fournier MJ, Boeke JD. RNA. 1998; 4:1096. [PubMed: 9740128]

10. Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC. *Cell*. 2007; 130:89. [PubMed: 17599402]
11. Ruby JG, Jan CH, Bartel DP. *Nature*. 2007; 448:83. [PubMed: 17589500]
12. Hasselberth JR. *WIREs RNA*. 2013; 4:677. [PubMed: 23881603]
13. Montemayer EJ, Katolik A, Taylor AB, Scheurmann J, Combs DJ, Johnsson R, Holloway SP, Stevens SW, Damha MJ, Hart PJ. *Nucleic Acids Res*. 2014; 42:10845. [PubMed: 25123664]
14. Matange N, Podobnik M, Visweswariah SS. *Biochem J*. 2015; 467:201. [PubMed: 25837850]
15. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. *Science*. 2006; 314:130. [PubMed: 17023659]
16. Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ. *Acta Neuropathol*. 2007; 114:63. [PubMed: 17492294]
17. Armakola M, Higgins MJ, Figley MD, Barmada SJ, Scarborough EA, Diaz Z, Fang X, Shorter J, Krogan NJ, Finkbeiner S, Farese RV Jr, Gitler AD. *Nat Genet*. 2012; 44:1302. [PubMed: 23104007]
18. Guschlbauer W, Krzysyt J. *Nucleic Acids Res*. 1980; 8:1421. [PubMed: 7433125]
19. Lackey JG, Mitra D, Somoza MM, Cerrina F, Damha MJ. *J Am Chem Soc*. 2009; 131:8496. [PubMed: 19485360]
20. Katolik A, Johnsson R, Montemayor E, Lackey JG, Hart JP, Damha MJ. *J Org Chem*. 2014; 79:963. [PubMed: 24401015]
21. Matray TJ, Gryaznov SM. *Nucleic Acids Res*. 1999; 27:3976. [PubMed: 10497261]
22. Lietard J, Ittig D, Leumann C. *J Bioorg Med Chem*. 2011; 19:5869.
23. Mignet N, Gryaznov SM. *Nucleic Acids Res*. 1998; 26:431. [PubMed: 9421496]
24. Robins MJ, Hawrelak SD, Hernandez AE, Wnuk SF. *Nucleosides, Nucleotides Nucleic Acids*. 1992; 11:821.
25. Op de Beeck M, Madder A. *J Am Chem Soc*. 2011; 133:796. [PubMed: 21162525]
26. Lohrmann R, Orgel LE. *J Mol Evol*. 1976; 7:253. [PubMed: 933177]
27. Krantz A. *Bioorg Med Chem Lett*. 1992; 2:1327.
28. Wang H, Hill K, Perry SE. *J Biol Chem*. 2004; 279:1468. [PubMed: 14570879]

Figure 1. Model of bRNA bound to Dbr1 and proposed hydrolytic mechanism.¹³

Figure 2.

(A) ^{31}P NMR spectra of compound **5** under the coupling conditions. (i) Compound **5** (ii) Compound **5** activated with ETT (iii) Compound **5** activated with DCI (B) Proposed structure of compound corresponds to the NMR peaks

Figure 3.

(A) ^{31}P NMR spectra of compound **9** under the coupling conditions. (i) Compound **9** (ii) Compound **9** activated with ETT (iii) Compound **9** activated with DCI (B) Proposed structure of compound corresponds to the NMR peaks

Figure 4. Ion exchange chromatographs of bN-RNA1 after exposure to several deprotection conditions.

Figure 5. (A) Schematic procedure of stability to debranching enzyme (B) PAGE result of the procedure; bN-RNA4 or bRNA5 (5 μM each) following 0.5 and 60 minute time points. The first lane features a ³²P-labelled synthetic product control (RNA6).

Figure 6.

(A) Schematic representation of the inhibition assay; (B) Products of reaction of Dbr1 + ³²P-bRNA5 as a function of increasing concentrations of bN-RNA4; (C) The structure of bN-RNA2 and bN-RNA4.

Scheme 1.

(A) Synthesis of the 2'-N-MMTr monomer **5** (B) Synthesis of the 2'-N-Fmoc monomer **9**

Scheme 2.

The divergent synthesis of 2',5' phosphoramidate linked bRNA employing monomer **9** at the branchpoint.

Table 1

List of branched RNAs synthesized in this study.

Entry	Molecule	Sequence (5'-3')	Isolated nmol ^a	Calculated mass	Observed mass
1	bN-RNA1 ^b	TTTTTA(2'-N-TTTT)TTTT	37	4826.8	4826.7
2	bN-RNA2	UAA(2'-N-GU)CA	52	2186.4	2186.3
3	bN-RNA3	UACUAA(2'-N-GUGUG)CAAGU	8.4 ^c	5102.7	5102.7
4	bN-RNA4	UACUAA(2'-N-GUAUG)CAAGU	28 ^d , 31 ^e	5088.7	5088.8

^aThe synthesis scale was 1 μmol, and ETT was used as an activator for all entries.

^bT in the sequence represents thymidine.

^cTEA·3HF was used as a de-silylating reagent.

^dTBAF in THF was used as a de-silylating reagent.

^eTEA·3HF/NMP/TEA was used as a de-silylating reagent.